COMPASS Pathways plc (NASDAQ:CMPS) Short Interest Down 6.2% in October

COMPASS Pathways plc (NASDAQ:CMPS) was the target of a large decline in short interest during the month of October. As of October 31st, there was short interest totalling 5,450,000 shares, a decline of 6.2% from the October 15th total of 5,810,000 shares. Based on an average daily volume of 751,300 shares, the short-interest ratio is presently 7.3 days.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. HC Wainwright lowered their price target on COMPASS Pathways from $120.00 to $60.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Royal Bank of Canada cut their target price on COMPASS Pathways from $23.00 to $18.00 and set an “outperform” rating for the company in a research note on Friday, November 1st. Maxim Group decreased their price target on shares of COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of COMPASS Pathways in a report on Monday, September 9th. Finally, Canaccord Genuity Group lowered their target price on shares of COMPASS Pathways from $50.00 to $48.00 and set a “buy” rating on the stock in a research note on Friday, August 2nd. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, COMPASS Pathways has an average rating of “Buy” and a consensus target price of $30.67.

COMPASS Pathways Trading Down 7.5 %

CMPS opened at $4.66 on Tuesday. The company has a quick ratio of 8.91, a current ratio of 8.91 and a debt-to-equity ratio of 0.15. The firm’s 50-day simple moving average is $6.09 and its 200-day simple moving average is $6.79. COMPASS Pathways has a twelve month low of $4.05 and a twelve month high of $12.75.

COMPASS Pathways (NASDAQ:CMPS) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.60) by $0.04. During the same quarter in the prior year, the firm earned ($0.67) EPS. As a group, sell-side analysts forecast that COMPASS Pathways will post -2.33 EPS for the current fiscal year.

Insider Buying and Selling

In other COMPASS Pathways news, major shareholder Life Sciences N.V. Atai sold 2,660,000 shares of the stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $6.05, for a total value of $16,093,000.00. Following the completion of the sale, the insider now directly owns 6,905,774 shares of the company’s stock, valued at $41,779,932.70. This represents a 27.81 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 4.25% of the stock is owned by insiders.

Institutional Investors Weigh In On COMPASS Pathways

Large investors have recently bought and sold shares of the business. Logos Global Management LP grew its holdings in shares of COMPASS Pathways by 349.3% during the second quarter. Logos Global Management LP now owns 1,159,030 shares of the company’s stock worth $7,001,000 after purchasing an additional 901,050 shares during the last quarter. Renaissance Technologies LLC increased its position in COMPASS Pathways by 1,518.4% in the 2nd quarter. Renaissance Technologies LLC now owns 263,800 shares of the company’s stock valued at $1,593,000 after acquiring an additional 247,500 shares in the last quarter. Hennion & Walsh Asset Management Inc. acquired a new stake in COMPASS Pathways in the 2nd quarter valued at about $664,000. Tidal Investments LLC raised its stake in shares of COMPASS Pathways by 43.6% in the first quarter. Tidal Investments LLC now owns 19,082 shares of the company’s stock worth $159,000 after acquiring an additional 5,795 shares during the last quarter. Finally, Virtu Financial LLC acquired a new position in shares of COMPASS Pathways during the first quarter worth approximately $201,000. 46.19% of the stock is currently owned by institutional investors.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.